Targeting SARS-CoV-2 spike protein by stapled hACE2 peptides

Marijn N. Maas, Jordi C. J. Hintzen, Philipp M. G. Löffler, Jasmin Mecinović*

*Corresponding author for this work

Research output: Contribution to journalJournal articleResearchpeer-review

66 Downloads (Pure)


SARS-CoV-2 Spike protein RBD interacts with the hACE2 receptor to
initiate cell entry and infection. We set out to develop lactam-based i,
i + 4 stapled hACE2 peptides targeting SARS-CoV-2. In vitro screening
demonstrates the inhibition of the Spike protein RBD-hACE2 complex
formation by the hACE221-55A36K-F40E stapled peptide (IC50: 3.6 lM,
Kd: 2.1 lM), suggesting that hACE2 peptidomimetics could form the
basis for the development of anti-COVID-19 therapeutics.
Original languageEnglish
JournalChemical Communications
Issue number26
Pages (from-to)3283-3286
Publication statusPublished - 2021


Dive into the research topics of 'Targeting SARS-CoV-2 spike protein by stapled hACE2 peptides'. Together they form a unique fingerprint.

Cite this